

Katılımcıları göster

## Approved nucleic acid therapeutics

Trade name	Target disease	Approved country/year	Vector	
Vitravene	CMV retinitis	USA (1998), Europe (1999)	oligonucleotide	
Gendicine	Head and neck cancers	China (2003)	adenovirus	
Oncorine	Nasopharyngeal cancer	China 2005	adenovirus	
Rexin-G	Soft tissue sarcoma, osteosarcoma, and pancreatic cancer	Philippine (2007)	retrovirus	
Neovasculgen	Atherosclerotic peripheral arterial disease	Russia (2011)	plasmid	
Glybera b	Familial lipoprotein lipase deficiency	Europe (2012)	AAV	
Zincmapro	Hypercholesterolemia	USA (2013)	oligonucleotide	

UZAN EMEL EYİPOĞLU (Konuş)



Fatma İskide AK...



Hacı KAR...



Ayşe Hacı



Fatma İskide AKBUĞA

46 / 53
 
 ...



Fatma Julide AK...



Hacı KAR...



Ayşegül HOŞ



Şevket DEM...



Maryem Nu...

+20



## Katılımcılar

Daveti paylaş

## Sunucular (5)



Ayşegül HOŞ



Fatma Julide AKBUĞA

## Katılımcılar (25)



Gülşem Zehra ÖMÜRBAĞ



Ayşe İNÇİ



Ayşegül ÇAŞKURLU



Barkın BERK



Berril ŞİRİN




Bişra İyş TÖK




Bişra Nur ÇATIK




Bişra ŞAHİN KURT



## Extracellular barriers



## Intracellular barriers



McCRUDEN &amp; McCarthy

UZAN İMRE EYLÜĞÜ (Konuş)



Fatma İzzet AK...



Hacı KAR...



Aygül HOŞ...



+22



&lt; 17 / 53 &gt; ...

Fatma İzzet AKBUĞA



Fatma İzzide AKBUĞA



Hacı KARAKAYA



Ayşe HÖRMEZ



+19



## Today and tomorrow

novel therapy development tools/platforms advances in bioanalytical methods (such as genome sequencing), and genome editing and manipulation technologies (such as molecular switches)

neuro-muscular diseases

